30 Apr 2019

Mereo BioPharma Group plc

("Mereo" or the "Company" or the "Group")

Notification of Director Dealing

 

London, April 30, 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 29 April 2019, Peter Fellner, Chairman of Mereo BioPharma, purchased 30,000 new ordinary shares in the Company at a price of GBP1.28 per share, as set out in the table below.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation.  The form required under the EU Market Abuse Regulation follows.

1

Details of the person discharging managerial responsibilities

a)

Name

Peter Fellner

2

Reason for the notification

a)

Position/status

Chairman

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

 

b)

Nature of the transaction

PURCHASE OF ORDINARY SHARES

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

GBP1.28

30,000

 

 

 

d)

Aggregated information:  volume, Price

Aggregated volume: 30,000 ordinary shares

Aggregated price: GBP1.28

e)

Date of the transaction

2019-04-29

f)

Place of the transaction

AIMX


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END